Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax Monotherapy in Indolent Lymphoma (Treatment-Naïve or BTK Intolerant)
ChiCTR2600121485Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lisaftoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), marginal zone B-cell lymphoma (MZL) and 1 more (2 cohorts), sponsored by Henan Cancer Hospital. Primary endpoints: Progression-free survival, Overall survival and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)lymphoma
Beyond the preview
Go deeper on ChiCTR2600121485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121485.